Stocks are facing serious headwinds: inflation, a hawkish Federal Reserve, the war in Ukraine, and Chinese growth worries. And it’s resulted in an epic sell-off. The broader markets entered 2022 on a high note with most of Wall Street looking for another year of solid gains.

But that hasn’t happened. The outlook for the broader stock market remains bearish. U.S inflation is at a 40-year high and Canadian inflation is running at its quickest pace in 31 years.1,2

Fears of a recession are sending investors to safe haven investments with a history of providing stable revenue growth and reliable earnings. One sector that investors are turning to amidst the global volatility is healthcare.

Source: Schwab.com

As of this writing, the S&P 500 Health Care Index is up 16% year-over-year while the Health Care Select Sector SPDR Fund is up 7.5% over the last 12-months. Over the same time frame the S&P 500 is down one percent, the Dow Jones Industrial Average has fallen 3.6%, and the Nasdaq is off 9.5%.

Even during recessionary periods healthcare stocks tend to provide more stable earnings and outpace the broader stock market. Analysts at JPMorgan Chase & Co have noted that healthcare stocks provide “defensive growth, high margins and pricing power, and attractive shareholder yield at a reasonable valuation.”3

Growth Prospects for Leading Healthcare Companies

Pfizer, Acquiring ReViral

Pfizer Inc. recently announced it was acquiring ReViral Ltd for up to $525 million. ReViral, a privately held drug maker, is developing medicines for a life-threatening respiratory virus. Pfizer said it believes ReViral’s programs, if successful, could generate annual revenue of more than $1.5 billion.4

Pfizer also announced that its COVID-19 pill, Paxlovid, will be available at pharmacies across the country, as the BA.2 sub-variant drives an uptick in cases. Paxlovid is poised to be one of the fastest-selling therapies of all time, with revenue estimates of almost $24 billion in 2022.5

NiseriN/iStock/Getty Images Plus
Source: NiseriN/iStock/Getty Images Plus

Novo Nordisk, Expanding Treatments

Novo Nordisk A/S is a global leader in branded diabetes markets, capturing 30% of the U.S. market. Novo Nordisk is also a global leader in obesity prescription drugs, with a 78% market share. Combined, these two markets are worth more than $100 billion, and are growing annually by double digits. By 2025, the company wants to expand into cardiovascular and chronic kidney disease treatments.6

Source: APSTOCK

LIFE ETF: Investing in the Healthcare Industry

One way to simplify investing in the cutting-edge healthcare industry is through an ETF. A healthcare ETF offers a diversified portfolio of holdings in healthcare stocks. ETFs ensure that your risk is diversified, but that you are still invested in blue-chip names that you trust.

Evolve Global Healthcare Enhanced Yield Fund (LIFE ETF) provides investors with exposure to twenty global blue-chip companies in the healthcare industry, with a covered call strategy that is actively managed to provide increased yield potential while helping mitigate risk. LIFE ETF is available in hedged, unhedged and USD classes, as well as mutual fund versions.

For more information about the Evolve Global Healthcare Enhanced Yield Fund or any of Evolve ETF’s lineup of exchange-traded funds, please visit our website or contact us.

For the latest information on investing in healthcare and updates on related investment products, sign up for our weekly newsletter here.

Sources:

  1. Jordan, D. “Soaring petrol prices send US inflation to 40-year high,” BBC, April 12, 2022; https://www.bbc.com/news/business-61083104.
  2. Evans, P. “Canada’s inflation rate jumps to new 31-year high of 6.7%,” CBC, April 20, 2022; https://www.cbc.ca/news/business/canada-inflation-1.6424388.
  3. Flanagan, C. “Healthcare stocks have record week as investors run for safety,” The Economic Times, April 9, 2022; https://economictimes.indiatimes.com/markets/stocks/news/healthcare-stocks-have-record-week-as-investors-run-for-safety/articleshow/90742049.cms.
  4. “Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates,” Pfizer Inc., April 7, 2022; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-reviral-and-its-respiratory-syncytial-virus.
  5. Paton, J. “Pfizer’s Covid Pill Is Poised to Be Among the Fastest-Selling Treatments of All Time,” Bloomberg, April 22, 2022; https://www.bloomberg.com/news/articles/2022-04-22/covid-antiviral-pills-seen-surging-after-slow-initial-uptake.
  6. “What We Do,” Novo Nordisk A/S, last accessed May 5, 2022; https://www.novonordisk.com/about/what-we-do.html.

 

The contents of this blog are not to be used or construed as investment advice or as an endorsement or recommendation of any entity or security discussed. These contents are not an offer or solicitation of an offer or a recommendation to buy or sell any securities or financial instrument, nor shall it be deemed to provide investment, tax or accounting advice. The information contained herein is intended for informational purposes only.
Commissions, management fees and expenses all may be associated with exchange traded funds (ETFs) and mutual funds (funds). Please read the prospectus before investing. ETFs and mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated. There are risks involved with investing in ETFs and mutual funds. Please read the prospectus for a complete description of risks relevant to ETFs and mutual funds. Investors may incur customary brokerage commissions in buying or selling ETF and mutual fund units.
Certain statements contained in this blog may constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to a future outlook and anticipated distributions, events or results and may include statements regarding future financial performance. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “anticipate”, “believe”, “intend” or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Evolve Funds undertakes no obligation to update publicly or otherwise revise any forward-looking statement whether as a result of new information, future events or other such factors which affect this information, except as required by law.

Sign up for our newsletter

Disruptive and innovative trends are fundamentally transforming our world. Remain educated and be informed.